---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-014834"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-04-02T23:59:59+00:00"
generated_at: "2026-05-15T07:50:09.892778+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Lipocine's LPCN 1154 Phase 3 PPD trial misses primary endpoint; post hoc signals

## Summary
- Primary endpoint not met: no statistically significant HAM-D17 reduction vs placebo at hour 60 in full population (N=90).
- Post hoc analysis of participants with psychiatric history (n=54) showed nominal significant reductions from hour 12 through day 30.
- LPCN 1154 was well tolerated; no SAEs, excessive sedation, or treatment-related discontinuations reported.
- Company evaluating all options, including further LPCN 1154 development, strategic transactions, and FDA designations (breakthrough/fast track applied).

## SEC filing metadata
- accession: 0001493152-26-014834
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-04-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226014834/0001493152-26-014834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226014834/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-014834
- JSON: https://secwatch.observer/filing/0001493152-26-014834.json
- Plain text: https://secwatch.observer/filing/0001493152-26-014834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.